Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Antofagasta maintains FY production guidance

(Sharecast News) - Mining giant Antofagasta maintained its full-year production guidance of 660,000 to 700,000 tonnes on Wednesday despite seeing "significant volatility" in global markets. Antofagasta said it had delivered "a solid quarter of operating performance" in the three months ended 31 March, with copper production up 19.6% year-on-year, while gold and molybdenum production rose 28.8% and 14.8%, respectively. Copper sales surged 47.1% to 170.2 kilotons.

The FTSE 100-listed firm stated that its growth programme had continued to "make material progress", with its Centinela Second Concentrator Project and Los Pelambres' Growth Enabling Projects advancing well. At its Zaldívar site, Antofagasta said it was now entering "the final stages" of its Environmental Impact Assessment, and that it remains focused on the resolution of permitting during Q225.

"With global markets experiencing significant volatility, our efforts remain centred on delivering robust operational performance, continued cost discipline and the timely execution of our growth projects," said chief executive Iván Arriagada.

"The medium-term outlook for copper remains strong given its fundamental role in energy security and electrification, positioning it as a metal of the future. We remain well-positioned to meet the rising demand through our pipeline of projects currently under construction."

As of 0835 BST, Antofagasta shares were down 2.21% at 1,502.50p.

Reporting by Iain Gilbert at Sharescast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.